Transforming medical imaging for early disease detection
Nanoparticles are at the core of our business.
We are developing new ways — based on our proprietary nanoparticle technology — to allow doctors to identify the presence of cancer sooner and more specifically than current methods.
We aspire to provide the tools to detect cancer at an earlier stage when treatment is most effective.
MagSense® Imaging Agent Technology
Simple, bio-safe molecular imaging

How does MagSense® imaging technology work?
How is MagSense® better than other imaging methods?
How will MagSense® change cancer detection?
MagSense® Phase 1 Study – HER2 Breast Cancer
MagSense® HER2 Clinical Trial
Our novel MagSense® HER2 imaging agent using bio-safe magnetic nanoparticles is being tested to show whether it has the potential to non-invasively detect the spread of breast cancer to the regional lymph nodes, avoiding the need for intrusive biopsies.
We have completed enrolling additional patients in a multi-site Phase I study of the MagSense® HER2 imaging agent.

PrecisionMRX® Nanoparticles
Nanoparticles that can save lives
In addition to their use in our MagSense® technology for cancer detection using MRI (magnetic resonance imaging) and MRX (Magnetic Relaxometry), our proprietary PrecisionMRX® nanoparticles can be used in a number of other applications, including MPI (magnetic particle imaging), magnetically induced hyperthermia and others. They can even increase the effect of chemotherapeutic agents.
Read about the other ways PrecisionMRX® nanoparticles are being used.
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.